Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 4th Annual Oncology Innovation Summit (Transcript)
03:18pm, Tuesday, 30'th May 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) TD Cowen 4th Annual Oncology Innovation Summit May 30, 2023 12:30 PM ET Company Participants Izzy Lowy - SVP, Solid Organ Oncology Development Andres Sir
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
12:05pm, Friday, 26'th May 2023
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
Regeneron (REGN) Faces Challenges as Eylea Sales Decline
03:18pm, Friday, 19'th May 2023
Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.
Regeneron Announces Investor Conference Presentations
04:01pm, Thursday, 18'th May 2023
TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
The 7 Growth Stocks You Need to Own Now for Maximum Returns
03:15pm, Wednesday, 17'th May 2023
Although recent headwinds like stubbornly high inflation and the banking sector crisis knocked the wind out of several publicly traded enterprises, a select number of hardened survivors potentially re
Regeneron Pharmaceuticals, Inc. (REGN) Bank of America Global Healthcare Conference Call Transcript
10:19pm, Saturday, 13'th May 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Bank of America Global Healthcare Conference Call May 9, 2023 4:40 PM ET Company Participants Ryan Crowe - VP, IR Robert Landry - EVP, Finance & CFO Conf
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
06:35am, Friday, 05'th May 2023
Regeneron Pharmaceuticals Inc. NASDAQ: REGN gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.
Why Regeneron Pharmaceuticals Stock Is Tanking Today
01:23pm, Thursday, 04'th May 2023
Regeneron Pharmaceuticals posted overall positive 2023 Q1 results today. Even so, investors are concerned about the competitive positioning of the drugmaker's blockbuster eye-care treatment.
Regeneron (REGN) Q1 Earnings and Revenues Top Estimates
09:07am, Thursday, 04'th May 2023
Regeneron (REGN) came out with quarterly earnings of $10.09 per share, beating the Zacks Consensus Estimate of $9.25 per share. This compares to earnings of $11.49 per share a year ago.
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker
08:50am, Thursday, 04'th May 2023
Regeneron Pharmaceuticals beat first-quarter sales and profit calls, but Eylea revenue came up short and REGN stock tumbled. The post Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneym
Regeneron tops Q1 estimates but lowers margin guidance, sending stock lower
07:36am, Thursday, 04'th May 2023
Regeneron Pharmaceuticals Inc. ‘s stock REGN, +0.59% slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance for 2023. The Tarrytown, N.
LGND vs. REGN: Which Stock Is the Better Value Option?
12:57pm, Tuesday, 02'nd May 2023
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Ligand Pharmaceuticals (LGND) and Regeneron (REGN). But which of these two stocks presents investors with the
Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?
09:09am, Monday, 01'st May 2023
Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.
3 Biotech Stocks To Watch Today
01:00pm, Tuesday, 25'th Apr 2023
Biotech stocks for your late-April 2023 watchlist.
4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates
09:53am, Monday, 24'th Apr 2023
We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.
